

FUTURE ONCOLOGY

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES

A NEW MEDICINE PUBLICATION

VOLUME 7, NUMBER 1-12 INDEX

FEBRUARY 2005

TABLE OF CONTENTS

| | | |
|---|--|------|
| ANTICANCER DRUGS AND MARKETS | | |
| UPDATE ON SPINDLE POISONS — PART III | | |
| NOVEL AGENTS IN DEVELOPMENT | | |
| NOVEL MICROTUBULE STABILIZING COMPOUNDS OBTAINED FROM NATURAL SOURCES-EXTRACTS, AND SEMISYNTHETIC AND SYNTHETIC ANALOGS 1487 | | |
| Colchicine-Site Binders | | 1488 |
| <i>Curacin</i> | | 1488 |
| Combretastatins | | 1488 |
| <i>AVE806</i> | | 1488 |
| <i>Combretastatin A-4 prodrug (CA4P)</i> | | 1488 |
| <i>Oxi-4503</i> | | 1494 |
| Cryptophycins | | 1494 |
| <i>LY355703</i> | | 1495 |
| Discodermolide | | 1496 |
| Dolastatin and Analogs | | 1496 |
| <i>Auristatin PHE</i> | | 1497 |
| <i>Dolastatin 10</i> | | 1497 |
| <i>ILX-651</i> | | 1497 |
| <i>Symplostatin 1</i> | | 1498 |
| <i>TZT-1027</i> | | 1499 |
| Epothilones | | 1499 |
| <i>BMS-247550</i> | | 1501 |
| <i>BMS-310705</i> | | 1503 |
| <i>EPO906</i> | | 1503 |
| <i>KOS-862</i> | | 1504 |
| <i>ZK-EPO</i> | | 1505 |
| Eleutherobin | | 1505 |
| FR182877 | | 1505 |
| Halichondrin B | | 1506 |
| <i>E7389</i> | | 1506 |
| Halimide | | 1506 |
| <i>NPI-2352 and NPI-2358</i> | | 1506 |
| Hemiasterlins | | 1506 |
| <i>HTI-286</i> | | 1507 |
| Laulimalide | | 1507 |
| Maytansinoids | | 1507 |
| <i>Bivatuzumab mertansine</i> | | 1508 |
| <i>Cantuzumab mertansine</i> | | 1508 |
| <i>huN901-DM1/BB-10901TAP</i> | | 1509 |
| <i>MLN591DM1</i> | | 1511 |
| <i>My9-6-DM1</i> | | 1511 |
| <i>Trastuzumab-DM1</i> | | 1512 |
| PC-SPES | | 1512 |
| Peloruside A | | 1513 |
| Resveratrol | | 1513 |
| S-allylmercaptocysteine (SAMC) | | 1513 |
| Spongistatins | | 1513 |
| Vitilevuamide | | 1513 |
| MOLECULAR MOTOR-KINESINS | | 1513 |
| SB-715992 | | 1514 |
| DESIGNED COLCHICINE-SITE BINDERS | | 1515 |
| A-289099 | | 1515 |
| A-293620/A-318315 | | 1515 |
| ABT-751/E7010 | | 1516 |
| D-24851/D-64131 | | 1517 |
| ZD6126 | | 1517 |
| OTHER NOVEL SPINDLE POISONS | | 1519 |
| 2-Methoxyestradiol (2-ME2) | | 1519 |
| Bezimidazole Carbamates | | 1521 |
| <i>ANG 600 series</i> | | 1521 |
| <i>Mebendazole</i> | | 1521 |
| CP248/CP461 | | 1521 |
| HMN-214 | | 1522 |
| R440 | | 1523 |
| SDX-103 | | 1524 |
| T67/T607 | | 1524 |
| ANTIBIOTIC/ANTHRACYCLINE CYTOTOXICS | | |
| PART I — | | |
| COMMERCIALLY AVAILABLE DRUGS | | |
| APPLICATIONS OF ANTIBIOTICS AS CYTOTOXICS | | 1529 |
| Mechanism of Action | | 1529 |
| Drug Resistance | | 1530 |
| <i>Tariquidar</i> | | 1530 |
| <i>Valspodar</i> | | 1532 |
| <i>Zosuquidar</i> | | 1533 |
| <i>Lovastatin</i> | | 1534 |
| <i>Cerulenin</i> | | 1534 |
| <i>Novobiocin</i> | | 1534 |
| <i>Theanine</i> | | 1534 |
| Toxicity | | 1540 |
| <i>Bisoxipiperazines</i> | | 1541 |
| <i>Flavonoids</i> | | 1541 |
| <i>Ribonucleotide reductase inhibitors</i> | | 1541 |
| <i>Dosing schedule modifications</i> | | 1542 |
| COMMERCIALLY AVAILABLE ANTHRACYCLINES | | 1542 |
| Daunorubicin | | 1542 |
| <i>DaunoXome</i> | | 1542 |
| Doxorubicin | | 1543 |
| <i>Intrahepatic administration</i> | | 1543 |
| <i>Liposomal doxorubicin</i> | | 1543 |
| <i>Myocet</i> | | 1544 |
| Epirubicin | | 1544 |
| Idarubicin | | 1545 |
| Mitoxantrone | | 1545 |
| OTHER COMMERCIALLY AVAILABLE ANTIBIOTIC CYTOTOXICS | | 1545 |
| Bleomycin | | 1545 |
| <i>Locally administered</i> | | 1546 |
| Dactinomycin | | 1546 |
| Gemtuzumab Ozoгамicin | | 1546 |
| Mitomycin | | 1546 |
| <i>Mitozytrex</i> | | 1546 |
| Plicamycin | | 1547 |
| ANTICANCER AGENTS FROM ANTIBIOTIC SOURCES | | |
| PART II — | | |
| NOVEL AGENTS IN DEVELOPMENT | | |
| NOVEL ANTICANCER ANTIBIOTICS | | 1550 |
| Actinonin Analogs | | 1550 |
| Anthracyclines | | 1551 |
| <i>GPX-100 and GPX-150</i> | | 1551 |
| <i>MEN 10755</i> | | 1551 |
| <i>PNU-159548</i> | | 1552 |

| | | | | | |
|--|------|--|------|--|------|
| <i>WP631</i> | 1553 | CMC-544 | 1582 | RANDOMIZED AND LARGE CLINICAL TRIALS IN ONCOLOGY | 1603 |
| <i>WP744</i> | 1553 | Cytotoxic Peptide Conjugates Targeted to their Receptors on Tumors | 1582 | Ethics of Large Clinical Trials in Oncology | 1603 |
| <i>WP760</i> | 1554 | <i>AN 152 and AN-207</i> | 1582 | The Impact of Pharmacogenomics | 1604 |
| <i>WP900</i> | 1554 | <i>AN-215</i> | 1583 | Design of Clinical Trials for New Molecularly Targeted Compounds | 1605 |
| Celeptium | 1554 | <i>AN-238</i> | 1583 | Randomized Discontinuation Design | 1605 |
| Distamycin A | 1554 | <i>C-terminal gastrin heptapeptide-targeted cytotoxics</i> | 1583 | Relationship Between Response Rate and Survival | 1605 |
| <i>Brostallicin</i> | 1554 | Davanat-2 | 1583 | OVERSIGHT IN CLINICAL DEVELOPMENT OF ANTICANCER DRUGS | 1605 |
| Duocarmycin | 1556 | HPMA-HA-DOX | 1583 | Centralized Review Boards | 1606 |
| <i>CC-1065 analogs</i> | 1556 | Immunoliposomes | 1583 | Conflict of Interest Guidelines | 1606 |
| <i>KW-2189</i> | 1556 | <i>Anti-HER2/doxorubicin immunoliposomes</i> | 1584 | DRUG COMBINATION STRATEGIES IN ONCOLOGY | 1606 |
| Elsamitrucin | 1557 | <i>EGFr-targeted/epirubicin immunoliposomes</i> | 1585 | Colorectal Cancer | 1606 |
| Enediynes | 1557 | <i>MCC-465</i> | 1585 | Lung Cancer | 1607 |
| <i>C-1027</i> | 1557 | SGN-15 | 1585 | Mesothelioma | 1607 |
| <i>Calicheamicin</i> | 1557 | Vitamin-mediated Targeted Delivery | 1586 | Prostate Cancer | 1607 |
| <i>Lidamycin</i> | 1557 | PRODRUGS | 1586 | Biochemotherapy in Metastatic Melanoma | 1607 |
| <i>Neocarzinostatin</i> | 1558 | CPI-0004Na | 1586 | MARKETS OF NEW ANTICANCER DRUGS | 1607 |
| FK317 | 1558 | CRX-103 | 1587 | NOVEL AGENTS IN RANDOMIZED CLINICAL TRIALS REPORTED AT ASCO03 | 1610 |
| Geldanamycin/Ansamycin and Analogs | 1558 | Epidoxiform | 1587 | <i>Æ-941</i> | 1610 |
| <i>17-(allylamino)-17-demethoxygeldanamycin (17-AAG)</i> | 1559 | L-377202 | 1587 | Atrasentan | 1611 |
| <i>17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG; NSC-707545)</i> | 1561 | Plasmin-targeted Doxorubicin | 1587 | Bevacizumab | 1613 |
| <i>CNF-101 and analogs</i> | 1561 | NOVEL FORMULATIONS | 1588 | BMS-247550 | 1615 |
| Indolocarbazole Antibiotics | 1566 | Liposomal/PEG Formulations | 1588 | CeaVac | 1616 |
| <i>CNF-101 and analogs</i> | 1561 | <i>Liposome-encapsulated Doxorubicin (LED)</i> | 1588 | CCI-779 | 1617 |
| <i>AT2433-A1, AT2433-A2, AT2433-B1 and AT2433-B2</i> | 1566 | MTC-DOX | 1588 | Cetuximab | 1617 |
| <i>CEP-701</i> | 1566 | P8ODOX-NP | 1589 | Gefitinib | 1618 |
| <i>DEAE rebeccamycin (XL 119)</i> | 1568 | Resmycin | 1589 | Irofulven | 1619 |
| <i>J-107088</i> | 1570 | SMANCS | 1590 | LY900003 | 1620 |
| <i>PKC412</i> | 1570 | SYN 2002 | 1590 | Pemetrexed | 1621 |
| <i>UCN-01</i> | 1571 | Transdrug Doxorubicin | 1591 | Provenge | 1624 |
| Mithramycin Analogs | 1574 | MEETING COVERAGE | | PSA-based Vaccine | 1625 |
| Prodigiosins | 1574 | RANDOMIZED CLINICAL TRIALS WITH NOVEL ANTICANCER AGENTS — | | Rubitecan | 1626 |
| Rapamycin/Sirolimus | 1575 | FROM THE 2003 MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) | | Satraplatin | 1627 |
| <i>AP23573/AP23675, AP23675 and AP23841</i> | 1576 | INCREASED EMPHASIS IN ALL ASPECTS OF CLINICAL TRIALS IN ONCOLOGY | 1593 | Thalidomide | 1627 |
| <i>CCI-779</i> | 1577 | Efforts to Increase Patient Participation | 1593 | Tirapazamine | 1628 |
| <i>RAD1000</i> | 1579 | Streamlining Cancer Drug Development | 1594 | | |
| Resveratrol | 1579 | Reporting and Registering Clinical Trials | 1594 | STATE-OF-THE-ART IN THE MANAGEMENT OF CANCER | |
| Salinospora | 1580 | | | PANCREATIC CANCER — PART I | |
| Spicamycin | 1580 | | | EPIDEMIOLOGY, ETIOLOGY, MOLECULAR MARKERS, DIAGNOSIS, AND STAGING | |
| <i>KRN 5500</i> | 1581 | | | TYPES OF PANCREATIC CANCER | 1633 |
| Taurolidine | 1581 | | | | |
| TARGETED CYTOTOXIC ANTIBIOTICS | 1581 | | | | |
| Biotinylated CBI-bearing CC-1065 Analogs | 1582 | | | | |
| Bispecific MAb | 1582 | | | | |

| | | | | | |
|---|------|---|------|--|------|
| Pancreatic Intraductal/Intraepithelial Neoplasia (PanIN) | 1633 | Surgery | 1665 | <i>S-CKD602</i> | 1706 |
| Exocrine Pancreatic Cancer | 1635 | Radiation Therapy (RT) | 1667 | Antimitotics/Spindle Poisons/Cell-Cycle Modulators | 1706 |
| <i>Pancreatic ductal adenocarcinoma (PDAC)</i> | 1635 | <i>External beam radiation therapy (EBRT)/3-dimensional conformal RT (3D-CRT)</i> | 1667 | <i>Cantuzumab mertansine</i> | 1706 |
| <i>Mucinous cystic neoplasms</i> | 1635 | <i>Intensity-modulated radiation therapy (IMRT)</i> | 1667 | <i>CRx-026</i> | 1707 |
| <i>Intraductal papillary mucinous tumors (IPMT)</i> | 1636 | <i>Intraoperative radiation therapy (IORT)</i> | 1668 | <i>DHA-paclitaxel</i> | 1707 |
| Neuroendocrine Pancreatic Tumors | 1637 | <i>Interstitial brachytherapy</i> | 1668 | <i>Disorazol E1</i> | 1708 |
| EPIDEMIOLOGY | 1637 | <i>Image-guided, fractionated, stereotactic radiosurgery</i> | 1669 | <i>DJ-927</i> | 1709 |
| ETIOLOGY OF PANCREATIC CANCER | 1637 | Chemotherapy | 1670 | <i>Flavopiridol</i> | 1709 |
| Epigenetic Events | 1637 | <i>5-Fluorouracil (5-FU)</i> | 1671 | <i>MBT-0206</i> | 1709 |
| Hereditary Factors | 1640 | <i>Arsenic trioxide</i> | 1687 | <i>Mebendazole (MZ)</i> | 1710 |
| Smoking | 1641 | <i>Capecitabine</i> | 1687 | Antimetabolites/Nucleoside Analogs | 1710 |
| Other Risk Factors | 1644 | <i>Celecoxib</i> | 1687 | <i>4'-thio-FAC</i> | 1714 |
| MOLECULAR MARKERS | 1644 | <i>Cisplatin</i> | 1687 | <i>Clofarabine</i> | 1715 |
| SCREENING | 1645 | <i>Cisplatin</i> | 1687 | <i>CYC682</i> | 1715 |
| DIAGNOSIS, PROGNOSIS AND DISEASE MONITORING | 1645 | <i>Docetaxel</i> | 1688 | <i>OSI-7836</i> | 1715 |
| Biopsy | 1645 | <i>Gemcitabine</i> | 1688 | <i>Tezacitabine</i> | 1716 |
| <i>In vitro</i> Diagnostics | 1646 | <i>Irinotecan</i> | 1689 | <i>Troxacitabine</i> | 1716 |
| <i>CA19-9</i> | 1647 | <i>Ocreotide acetate</i> | 1689 | Antimetabolites/Thymidylate Synthase (TS) | |
| <i>CA50</i> | 1647 | <i>Oxaliplatin</i> | 1690 | Inhibitors/Antifolates | 1717 |
| <i>CA195</i> | 1647 | <i>Virulizin</i> | 1691 | <i>AG2037</i> | 1717 |
| <i>CA242</i> | 1647 | Hyperthermia | 1691 | <i>BGC 9331</i> | 1718 |
| <i>Carbonic anhydrase 3 (CAR-3)</i> | 1660 | Photodynamic Therapy (PDT) | 1691 | <i>Daxxamat-1</i> | 1718 |
| <i>PaCa-Ag1</i> | 1660 | Electroporation Therapy (EDT) | 1692 | <i>Nolatrexed dihydrochloride</i> | 1718 |
| <i>Molecular Beacons</i> | 1660 | TREATMENT BY STAGE | 1692 | <i>Pemetrexed sodium</i> | 1719 |
| <i>In vivo</i> Diagnostics | 1660 | Resectable Locally Advanced Disease | 1693 | Alkylating Agents/Toxins | 1719 |
| <i>Endoscopic retrograde cholangiopancreatography (ERCP)</i> | 1661 | <i>Adjuvant Chemotherapy/CRT</i> | 1693 | <i>Glyfosfamide</i> | 1719 |
| <i>Endoscopic ultrasound (EUS)</i> | 1661 | Inoperable Locally Advanced Disease | 1695 | <i>Ifosfamide</i> | 1720 |
| <i>Computed tomography (CT)</i> | 1661 | <i>Chemoradiotherapy (CRT)</i> | 1695 | <i>Iroflufen</i> | 1721 |
| <i>Ultrasound imaging</i> | 1661 | <i>Intraoperative radiation therapy (IORT)</i> | 1698 | OTHER NOVEL ANTICANCER AGENTS | 1721 |
| <i>Magnetic resonance (MR)</i> | 1661 | Metastatic Disease | 1698 | MPC-6827 | 1721 |
| <i>Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET)</i> | 1662 | Pain Management | 1698 | Natural Products/Vitamin Analogs | 1721 |
| <i>OctreoScan</i> | 1663 | TREATMENT COSTS | 1699 | <i>Isoprenoids</i> | 1721 |
| STAGING OF PANCREATIC CANCER | 1663 | PANCREATIC CANCER — PART III | | <i>Perillyl alcohol</i> | 1722 |
| Incidence by Stage | 1663 | NOVEL CYTOTOXICS, HORMONE MODULATORS, FORMULATIONS/PRODRUGS AND RELATED AGENTS IN DEVELOPMENT | | <i>SR271425</i> | 1722 |
| 5-year Survival by Stage | 1663 | NOVEL CYTOTOXICS | 1702 | <i>Vitamin K₂</i> | 1722 |
| PANCREATIC CANCER — PART II | | Topoisomerase I Inhibitors | 1702 | Retinoids | 1722 |
| CURRENT DISEASE MANAGEMENT APPROACHES AND COMBINATION CHEMOTHERAPY/MULTIMODALITY CLINICAL TRIALS OF COMMERCIALY AVAILABLE ANTICANCER AGENTS | | <i>DX-8951f</i> | 1702 | AGN193198 | 1722 |
| CURRENT TREATMENT MODALITIES | 1665 | <i>DE-310</i> | 1703 | SDX-102 | 1722 |
| | | <i>LE-SN38</i> | 1703 | Triapine | 1723 |
| | | <i>MBT-0312</i> | 1704 | DIGESTIVE ENZYMES | 1724 |
| | | <i>Rubitecan</i> | 1705 | HORMONE MODULATORS | 1725 |
| | | | | RADIOSENSITIZERS/CHEMOSENSITIZERS | 1725 |
| | | | | CoFactor | 1725 |
| | | | | Motexafin Gadolinium | 1726 |
| | | | | O(6)-benzylguanine | 1726 |

LIST OF EXHIBITS

| TITLE | PAGE | TITLE | PAGE | TITLE | PAGE |
|---|------|--|------|--|------|
| Novel Spindle Poisons and Formulations | 1489 | Worldwide Markets of Selected Novel Anticancer Agents ¹ with Revenues of >\$100 Million Introduced Since 1990 | 1608 | Molecular Markers Associated with Pancreatic Cancer | 1648 |
| Selected Commercially Available Antibiotic Cytotoxics | 1531 | Anticancer Agents Granted Accelerated Approval by the FDA (1996-2003) | 1609 | Staging of Pancreatic Cancer | 1662 |
| Selected Clinical Trial Status of Novel Drugs Being Evaluated in Combination With Cytotoxic Antibiotics | 1535 | Worldwide Incidence of Pancreatic Cancer in 2002 | 1638 | Estimated Incidence by Stage of Pancreatic Cancer in the USA in 2003 and 5-year Survival | 1663 |
| Historic (2000-2001) and Forecast (2002) Global Markets of Ellence | 1547 | Worldwide Mortality from Pancreatic Cancer in 2002 | 1639 | Interim and Final Results from Selected Clinical Trials with Approved Chemotherapy Agents in Combination and Multimodality Regimens in Pancreatic Cancer | 1672 |
| Novel Antibiotics Cytotoxics in Development | 1562 | Incidence of Pancreatic Cancer in the Developed World in 2002 | 1642 | Worldwide Incidence of Pancreatic Cancer in 2002 | 1694 |
| Novel Anticancer Agents in Ongoing or Recently Completed Single-agent or Combination, Randomized, Phase III Clinical Trials | 1595 | Mortality from Pancreatic Cancer in the Developed World in 2002 | 1643 | Novel Cytotoxics, Hormone Modulators, Prodrugs/Formulations and Related Agents Evaluated Either Clinically or Preclinically for the Treatment of Pancreatic Cancer | 1711 |
| | | Estimated Age-adjusted Incidence Rates (per 100,000) by Age and Race in the USA (1966-2000) | 1647 | | |

INDEX OF COMPANIES & INSTITUTIONS

| | | | | | | | |
|--------------------------------------|--|--|--|---------------------------------------|--|------------------------------|--|
| Aarhus University Hospital (Denmark) | 1697 | Amersham Health | 1536 | Aventis Pasteur | 1538, 1596 | Bigmar | 1600 |
| Abbott Laboratories | 1489, 1490, 1497, 1515, 1516, 1517, 1531, 1538, 1595, 1601, 1611, 1613, 1713 | Amgen | 1531, 1545, 1595, 1599 | Aventis Pharma | 1488, 1489, 1490, 1521, 1709, 1712, 1716 | BioAlliance Pharma | 1562, 1591 |
| Abgenix | 1489, 1508 | AmpliMed | 1711 | Axcan Pharma | 1692 | Bioenvision | 1711, 1715 |
| Access Oncology | 1551, 1563, 1595, 1610 | Angiogene Pharmaceuticals | 1489, 1517, 1521 | Azienda Ospedaliera C. Poma (Italy) | 1685 | BioInvent International | 1596 |
| Accuray | 1669 | Ankara University (Turkey) | 1675 | Baltimore VA Medical Center | 1534 | biolitec Pharma | 1692 |
| Advectus Life Sciences | 1562, 1589 | AnorMED | 1539 | Banyu Pharmaceuticals | 1562, 1570 | BioMedicines | 1596 |
| Adventrx | 1711, 1725 | Antra Pharmaceuticals | 1531, 1542 | Barbara Ann Karmanos Cancer Institute | 1569, 1581 | Biomembrane Institute | 1596 |
| Aegera Therapeutics | 1535 | AntiCancer | 1715 | BASF Pharma | 1491, 1497 | bioMerieux | 1660 |
| Æterna Laboratories | 1582, 1595 | Antigenics | 1596, 1601 | BattellePharma | 1566, 1589 | Biomira | 1595, 1596 |
| Airedale General Hospital (UK) | 1703 | Antisoma | 1596 | Baxter Oncology | 1489, 1517, 1531, 1562, 1596, 1711 | BioNumerik Pharmaceuticals | 1596 |
| Ajinomoto | 1488, 1489 | Aphton | 1596 | Baxter International | 1517 | BioResearch Ireland | 1536 |
| Albert Einstein College of Medicine | 1486 | Ariad Pharmaceuticals | 1562, 1576 | Bayer | 1532, 1547 | Biovation | 1511 |
| Albert Ludwigs University (Germany) | 1498 | Arizona Cancer Center | 1498, 1522, 1680, 1717, 1718, 1721 | Baylor College of Medicine | 1725 | Boehringer Ingelheim | 1489, 1508, 1536, 1596, 1598 |
| Alfacell | 1536, 1595, 1711 | Arizona State University | 1487, 1488, 1489, 1491, 1492, 1494, 1496, 1497 | Beacon Pharmaceuticals | 1531 | Boston Scientific | 1602 |
| Allergan | 1711, 1722 | Arlington Cancer Center | 1532 | Beatson Oncology Centre (UK) | 1504 | BotanicLab | 1512 |
| Alliance Pharmaceutical | 1598 | Arthur G. James Cancer Hospital and Research Institute | 1704 | Beckman Research Institute | 1573 | Brady Urological Institute | 1635 |
| Allos Therapeutics | 1595 | Asta Medica | 1489, 1517 | Bedford Laboratories | 1531 | BrainLAB (Germany) | 1670 |
| AltaRex | 1595 | AstraZeneca | 1489, 1517, 1518, 1607, 1608, 1618, 1718 | Beijing Pason Pharmaceuticals | 1714, 1723 | Brigham and Women's Hospital | 1570 |
| Alza | 1531, 1543, 1562, 1585, 1706, 1711 | Australian National University | 1538 | Beijing University | 1535 | Bristol-Myers Squibb (BMS) | 1488, 1489, 1490, 1493, 1500, 1501, 1503, 1506, 1531, 1532, 1536, 1537, 1557, 1565, 1566, 1568, 1594, 1596, 1598, 1608, 1617, 1627 |
| American BioScience | 1595 | Austrianova | 1711, 1720, 1721 | Ben Venue Laboratories | 1531, 1532 | British Biotech | 1491, 1509, 1510 |
| American Pharmaceutical Partners | 1595 | Avecia | 1535, 1537, 1598 | Berlex Biosciences | 1714 | Brooke Army Medical Center | 1709, 1722 |
| | | Aventis | 1535, 1536, 1537, 1560, 1585, 1586, 1594, 1596, 1598, 1600, 1608, 1623, 1688 | Berlex Laboratories | 1608 | Bryn Mawr College | 1713 |
| | | | | Beth Israel Deaconess Medical Center | 1498 1675 | | |

| | | | | | | | |
|--|--|---|--|--|--|---|--|
| BSD Medical | 1691 | Christie Hospital NHS Trust (UK) | 1510, 1674, 1717 | Diatos | 1564, 1586 | Gem Pharmaceuticals | 1563 |
| BTG | 1711, 1718 | Children's Hospital (Boston) | 1490, 1536, 1597 | Dicle University (Turkey) | 1675 | Genentech | 1491, 1512, 1535, 1536, 1537, 1539, 1540, 1598, 1600, 1607, 1608, 1613 |
| Burnham Institute | 1562 | Chiron | 1599, 1607, 1608, 1712 | Dompe Farmaceutici | 1595 | GeneTex | 1723 |
| BZL Biologies | 1491, 1511 | Chong Kun Dang Pharmaceutical | 1706, 1711 | DOR BioPharma | 1536 | Genetronics Biomedical | 1546, 1598, 1692 |
| CAC (France) | 1619 | CHU (France) | 1619 | Dow Chemical | 1599 | Genitope | 1598 |
| CACF Baclesse (France) | 1620 | Chugai Lilly Clinical Research | 1535, 1536, 1597 | Dublin City University | 1536 | Gensia Sicor Pharmaceuticals | 1531 |
| Caltech | 1712 | Chugai Pharmaceutical | 1535, 1536, 1597 | Duke University | 1562, 1697 | Genta | 1535, 1537, 1598 |
| Cambridge University (UK) | 1496 | Ciphergen Biosystems | 1646 | Eastern Virginia Medical School | 1625 | Genzyme Molecular Oncology | 1537 |
| Canadian Genetic Diseases Network | 1535 | City of Hope | 1573, 1578 | Ecopia BioSciences | 1551, 1557 | Genzyme Transgenics | 1510 |
| Cancer Care Ontario | 1572, 1604 | City Hospital Nottingham (UK) | 1616 | Eisai | 1490, 1516 | Georgia Institute of Technology | 1660 |
| Cancer Institute Hospital (Japan) | 1585 | Clatterbridge Centre for Oncology (UK) | 1718 | Elan | 1531, 1544, 1563 | Georgetown University Medical Center | 1567 |
| Cancer Institute of New Jersey | 1503, 1705 | Clayton Foundation for Research | 1602, 1714 | Elekta | 1670, 1697 | Georgia Cancer Research Center | 1616 |
| Cancer Research Campaign (CRC) | 1493, 1539, 1560, 1561, 1711 | Cleveland Clinic Cancer Center | 1610 | Eli Lilly | 1490, 1533, 1535, 1536, 1538, 1555, 1586, 1594, 1597, 1599, 1600, 1607, 1608, 1620, 1621, 1623, 1624, 1670, 1688, 1702, 1712, 1719 | German Cancer Research Centre | 1711, 1714 |
| Cancer Research Center of Hawaii | 1507 | Columbia Presbyterian Medical Center | 1522, 1673 | Endorecherche | 1601 | Gesellschaft für Biotechnologische Forschung (GBF; Germany) | 1489, 1450, 1500, 1501 1503 |
| Cancer Treatment Centers of America | 1673 | Columbia University | 1495, 1522, 1687, 1725 | ENEA (Italy) | 1668 | Gilead Sciences | 1531, 1542, 1713, 1715, 1716 |
| Cancer Therapeutics | 1596 | CombinatoRx | 1707, 1712 | EntreMed | 1490, 1519, 1520, 1521, 1536, 1597 | GlaxoSmithKline | 1491, 1508, 1509, 1515, 1536, 1537, 1539, 1544, 1566, 1594, 1600, 1608, 1697, 1707 |
| Cancer Therapy and Research Center (CTRC) | 1508, 1509, 1510, 1515, 1523, 1702, 1703, 1721 | Conforma Therapeutics | 1559, 1561, 1562 | Enzon | 1531, 1544, 1702, 1712 | Goodwin Biotechnology | 1602 |
| Cancervax | 1596 | Copenhagen University Hospital (Denmark) | 1697 | Esterio Anstalt | 1599 | GPC Biotech | 1601, 1617 |
| Carl Zeiss | 1668 | Corporacio Sanitaria Parc Tauli (Spain) | 1680 | European Oncology Institute (IEO; Italy) | 1503 | Gray Cancer Institute (UK) | 1494 |
| Case Western Reserve University | 1722, 1727 | Corixa | 1536, 1596 | European Institute of Transuranium Elements (ITU) | 1600 | Greenebaum Cancer Center | 1495, 1534, 1573, 1615 |
| Catholic University (Belgium) | 1615 | Cornell University | 1511, 1597, 1718, 1724 | Exelixis | 1563, 1568 | Grelan Pharmaceutical | 1596 |
| CBA Pharma | 1596 | Covance Biotechnology Services | 1597 | Eximias Pharmaceutical | 1597, 1712 | Griffith University (Australia) | 1538 |
| CDS Systems | 1668 | Cyclacel | 1714, 1715 | Ferro Pfanstiehl Laboratories | 1711 | Grupo Ferrer Internacional | 1595 |
| Celanese | 1713 | Cytokinetics | 1491, 1515 | FeRx | 1563, 1588, 1589 | Gruppo Oncologico Italia Meridionale (GOIM) | 1678 |
| Celgene | 1536, 1597, 1608, 1627 | Cytoskeleton | 1487 | Florida Oncology Associates | 1532, 1718 | GTC Biotherapeutics | 1491, 1510 |
| Cell Genesys | 1508 | Daiichi Pharmaceutical | 1492, 1499, 1597, 1702, 1703, 1712 | Food and Drug Administration (FDA) | 1493, 1520, 1526, 1594, 1603, 1604, 1607, 1609, 1608, 1610, 1611, 1613, 1617, 1618, 1621, 1625, 1626, 1627, 1668, 1669, 1670, 1689, 1690, 1691, 1705, 1717, 1719, 1721 | Guys Hospital London (UK) | 1616 |
| Cell Pathways | 1521, 1522, 1536 | Dainippon Pharmaceutical | 1599, 1713 | Fordham University | 1596 | H. Lee Moffitt Cancer Center | 1681, 1704, 1718 |
| Cell Therapeutics | 1535, 1597, 1687 | Dana-Farber Cancer Center | 1644 | Foundation for NIH | 1594 | Hacettepe University (Turkey) | 1683 |
| Celltech Group | 1532, 1535, 1562, 1582, 1596 | Dana-Farber Cancer Institute | 1498, 1520, 1536, 1569, 1570, 1571, 1616, 1620 | Fox Chase Cancer Center | 1614, 1667, 1695 | Hamilton Regional Cancer Centre | 1572 |
| Celsion | 1562 | Dartmouth Hitchcock Medical Center | 1673, 1718 | Fred Hutchinson Cancer Research Center | 1532, 1535 | Harbor Branch Oceanographic Institution (HBOI) | 1487, 1496 |
| Center for Marine Biotechnology and Biomedicine (CMBB) | 1580 | Degussa | 1582 | Friends of Cancer Research | 1594 | Harper Hospital | 1634 |
| Center for Molecular Medicine and Immunology (CMMI) | 1537, 1669 | Dendreon | 1597, 1607, 1624, 1625 | Fujirebio Diagnostics | 1647 | Harvard College | 1500 |
| Centocor Diagnostics | 1647 | Department of Health and Human Services (HHS) | 1594 | Fujisawa Pharmaceutical | 1490, 1505, 1558, 1563 | Harvard Medical School | 1490, 1644, 1657, 1676 |
| Centre Hospitalier General (France) | 1615 | Diagnostic Products | 1646 | Garvan Institute of Medical Research (Australia) | 1634 | Harvard University | 1562 |
| Centre Val d'Aurelle (France) | 1619, 1686 | | | Gemeinschaftspraxis für Haematologie und Onkologie (Germany) | 1624 | Henry Ford Cancer Center | 1487 |
| Cephalon | 1566 | | | | | Herbert Irving Comprehensive Cancer Center | 1725 |
| Charité Campus Virchow-Klinikum (Berlin) | 1684 | | | | | | |
| Charité Medical School | 1691 | | | | | | |

| | | | | | | | |
|--|--|---|---|--|--|--|---|
| Hermes Biosciences | 1584, 1585 | Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD; France) | 1513 | Klinik für Strahlentherapie und Radioonkologie (Germany) | 1676 | Medac | 1532, 1595 |
| Hillman Cancer Center | 1726 | Institut Gustave Roussy (France) | 1610, 1615, 1619 | Kliniken-Essen-Mitte (Germany) | 1708 | MedActinium | 1600 |
| Hitesys (Italy) | 1668 | Institut Jules-Bordet (Belgium) | 1618 | Kobe City General Hospital (Japan) | 1682 | Medarex | 1564, 1586, 1598 |
| Hoechst Celanese | 1538, 1601 | Institut Paoli Calmettes (France) | 1686 | Kochi Municipal Central Hospital (Japan) | 1684 | Medicines Control Agency (UK) | 1510 |
| Hoffmann-La Roche | 1491, 1523, 1535, 1536, 1537, 1538, 1539 | Instituto Arnaldo Vieira de Carvalho (Brazil) | 1623 | Kosan Biosciences | 1491, 1496, 1500, 1504, 1505, 1507 | Medison Pharma | 1595, 1596 |
| Hoosier Oncology Group | 1673 | Institute for Drug Development | 1578, 1709 | Krankenhaus Grossshansdorf (Germany) | 1496, 1620 | MegaPharm | 1599 |
| Hôpital Saint Antoine | 1690 | Institute of Biomedical Research and Innovation (Japan) | 1682 | Krankenhaus Nordwest (Germany) | 1708 | Mehr Medical Center (Iran) | 1627 |
| Hôpital Tenon (France) | 1619 | Institute of Medical Oncology (Switzerland) | 1677 | Kosan Biosciences | 1563 | MDS Nordion | 1536 |
| Hospital Aleman (Argentina) | 1619 | Instituto Nazionale per la Ricerca sul Cancro (Italy) | 1615 | Kyoto University (Japan) | 1692, 1698 | Medical Center of Vincennes | 1532 |
| Hospital Germans Trias (Spain) | 1623 | International Medac | 1595 | Kyowa Hakko Kogyo | 1537, 1563, 1566, 1571, 1599, 1712, 1716 | MediciNova | 1521 |
| Hospital Pitie-Salpetriere (France) | 1617, 1618 | Intracel | 1599 | Laboratories Thissen | 1531 | Medigen Biotechnology | 1538 |
| Hospital Universitario 12 de Octubre (Spain) | 1534, 1615, 1621, 1623 | Intraop Medical | 1668 | Leicester Royal Infirmary (UK) | 1616, 1717 | Meiji Pharmaceutical University | 1534 |
| Hospital Universitario Central de Asturias (Spain) | 1553 | Introgen Therapeutics | 1521, 1537, 1599, 1710, 1712 | Lombardi Cancer Center | 1567 | Meiji Seika Pharma International | 1531 |
| Hospitiaux de Lyon (France) | 1683 | Ireland Cancer Center | 1494, 1569, 1622, 1719, 1727 | Lorus Therapeutics | 1691 | Memorial-Sloan Kettering Cancer Center (MSKCC) | 1491, 1499, 1500, 1501, 1504, 1523, 1524, 1535, 1550, 11559, 1560, 1562, 1568, 1571, 1573, 1577, 1598, 1600, 1616, 1621, 1667, 1696, 1702, 1709, 1723 |
| Humboldt University (Germany) | 1691 | Isis Pharmaceuticals | 1599, 1607, 1624 | Louisiana State University | 1537 | Memorial Sloan-Kettering Institute for Cancer Research | 1504, 1505 |
| Hybridon | 1537 | Istituto Clinico Humanitas (Italy) | 1618 | LSU Health Sciences Center | 1689 | Memphis Cancer Center | 1719 |
| Ibaraki Prefectural Central Hospital (Japan) | 1585 | Istituto Nazionale dei Tumori (INT; Italy) | 1503 | Ludwig Institute for Cancer Research | 1598 | Menarini Group | 1551, 1564 |
| IBC Pharmaceuticals | 1582 | James Graham Brown Cancer Center | 1554 | Luitpold Pharmaceutical | 1707, 1713 | Mentor | 1599 |
| Icos | 1565 | Janssen Pharmaceutica | 1537, 1599 | MacroMed | 1713 | Mercian (Japan) | 1531, 1542 |
| IDEC Pharmaceuticals | 1535, 1576, 1608 | Japan Tobacco | 1489, 1508 | Mallinckrodt | 1663 | Merck | 1499, 1532, 1564, 1570, 1587 |
| IDIS World Medicines | 1535 | Jefferson Medical College | 1668 | Mario Negri Institute | 1503 | Merck KGaA | 1537, 1596, 1598, 1617 |
| Ilex Oncology | 1491, 1497, 1498, 1598, 1711, 1715, 1717 | John Wayne Cancer Institute | 1596 | Martek Biosciences | 1713 | metaGen Pharmaceuticals | 1492, 1505 |
| ImClone Systems | 1537, 1595, 1598, 1603, 1607 | Johns Hopkins University School of Medicine | 1635, 1636, 1639, 1640, 1646, 1657, 1667, 1702, 1708, | Martek Biosciences | 1713 | MGI Pharma | 1599, 1619, 1713, 1721 |
| Immune Response | 1597 | Johnson & Johnson | 1529, 1531, 1543, 1585, 1598, 1608 | Martin Luther University (Germany) | 1624 | Millennium Pharmaceuticals | 1491, 1511, 1537, 1670 |
| Immuno-Designed Molecules (IDM) | 1598 | Johnson Matthey | 1601 | Mary Crowley Medical Research Center | 715 | Mitsubishi Pharma | 1585 |
| ImmunoGen | 1489, 1491, 1507, 1508, 1509, 1510, 1511, 1512, 1536, 1537, 1539, 1540, 1598, 1706, 1707, 1712 | Jonsson Comprehensive Cancer Center | 1578, 1621 | Massachusetts General Hospital | 1594, 1692 | Mitsui Pharmaceuticals | 1537 |
| Immunomedics | 1537, 1582, 1599 | JT America | 1508 | Massachusetts Institute of Technology (MIT) | 1562 | Moffitt Cancer Center and Research Institute | 1501 |
| Impath | 1598 | Kagoshima University School of Medicine (Japan) | 1696 | Mastology Research Institute | 1584 | Molecular Biosystems | 1535, 1537 |
| Imperial Cancer Research Fund (ICRF) | 1596 | Karmanos Cancer Institute | 1502, 1674, 1704, 1709, 1721 | M. D. Anderson Cancer Center (MDACC) | 1497, 1510, 1523, 1532, 1537, 1547, 1597, 1599, 1610, 1641, 1679, 1684, 1685, 1709 | Molecules for Health | 1538, 1541 |
| Indiana Oncology Hematology Center | 1719 | Keryx Biopharmaceuticals | 1713, 1726, 1727 | Maxim Pharmaceuticals | 1599, 1713, 1721 | Montefiore Medical Center | 1526 |
| Indiana University | 1520, 1533, 1601, 1623, 1673, 1680, 1721, 1722 | Kinki University School of Medicine (Japan) | 1516 | Mayne Pharma | 1532, 1599 | Morristown Memorial Hospital | 1673 |
| Indiana University Cancer Center | | Kirin | 1563, 1581, 1597 | Mayo Clinic | 1497, 1502, 1519, 1520, 1560, 1579, 1597, 1617 | Mount Sinai School of Medicine | 1596, 1696 |
| Indiana University School of Medicine | | | | McGill University (Canada) | 1610 | Mount Vernon Hospital Northwood (UK) | 1493, 1494 |
| Industrial Research | 1491, 1507, 1712 | | | McMaster University | 1545 | Munich Biotech | 1704, 1709, 1710, 1713 |
| Insert Therapeutics | 1712 | | | | | Myriad Genetics | 1713, 1721 |
| | | | | | | Nagasaki University | 1534 |

| | | | | | | | |
|---|--|--|--|--|------------------------------------|---|--|
| Nagoya University | 1496 | Northside Hospital Cancer Center (Atlanta) | 1669 | Pharmacyclics | 1538, 1601, 1713, 1726 | Rutgers University | 1721 |
| National Cancer Center Hospital (Japan) | 1570, 1666, 1671, 1682 | Nottingham City Hospital | 1510, 1527 | PharmaMar | 1538, 1554 | Rush Medical College | 1615 |
| National Cancer Center Hospital East (Japan) | 1683, 1686, 1696 | Novartis | 1487, 1492, 1496, 1500, 1503, 1594, 1600, 1603, 1608, 1663, 1670, 1689, 1725 | Pharmion | 1536, 1601 | Sahlgrenska University Hospital (Sweden) | 1711, 1726 |
| National Cancer Institute (NCI) | 1487, 1497, 1500, 1504, 1506, 1513, 1519, 1520, 1532, 1533, 1535, 1538, 1550, 1554, 1563, 1564, 1568, 1571, 1572, 1573, 1574, 1578, 1581, 1584, 1585, 1594, 1595, 1599, 1606, 1610, 1626, 1690, 1711, 1723, 1724, 1727 | Novartis Pharmaceuticals | 1532, 1535, 1539, 1564, 1570, 1579 | Pharsight | 1537 | Saint Vincent's Cancer Care Center | 1685 |
| National Cancer Hospital (Korea) | 1523 | Novuspharma | 1600 | Philipps University (Germany) | 1640 | Sakai Chemical Industry | 1601 |
| National Cancer Institute of Canada (NCIC) | 1715 | NS Pharma | 1492, 1522 | Pierre Fabre Oncologie | 1540 | Salisbury District Hospital (UK) | 1675 |
| National Cell and Tissue Culture Centre (NCTCC) | 1536 | Oak Ridge National Laboratory (ORNL) | 1600 | Pneumological Hospital 'C Forlanini' (Italy) | 1623 | Salk Institute | 1713 |
| National Centre for Cancer Treatment (UK) | 1504 | Ochsner Cancer Institute | 1718 | PolyMASC Pharmaceuticals | 1538, 1540, 1600 | Salmedix | 1492, 1524, 1714, 1722, 1723 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1500 | Ohio State University | 1594, 1704 | Polymedco | 1647 | Sam Waxman Cancer Research Foundation | 1535 |
| National Institute of General Medical Sciences (NIGMS) | 1500 | OncoCenter (Spain) | 1678 | Praecis Pharmaceuticals | 1601 | Samsung Medical Center (Korea) | 1680, 1682 |
| National Institute of Health (NIH) | 1487, 1498, 1594, 1597, 1600, 1610, 1724 | Oncology Institute of Southern Switzerland (Istituto Oncologico della Svizzera Italiana or IOSI) | 1503 | Prince Charles Hospital (Australia) | 1621 | Samyang Genex | 1713 |
| National Medical Laser Centre (UK) | 1692 | Oncormed | 1537, 1599 | Prince of Wales Hospital (Australia) | 1672 | San Raffaele-H Scientific Institute (Italy) | 1677 |
| National Nagoya Hospital (Japan) | 1570 | ONYX Pharmaceuticals | 1538, 1540, 1600 | Princess Margaret Hospital (Canada) | 1503, 1574, 1623, 1716 | Sankyo | 1707, 1714, 1715 |
| Natural Pharmaceuticals | 1597 | Oregon Health Sciences University | 1535, 1539 | Princess Royal Hospital (UK) | 1620 | Sanofi-Synthelabo | 1538, 1601, 1607, 1608, 1628, 1690, 1714, 1722 |
| NCI | 1532 | Oregon State University | 1487, 1488, 1500 | Princeton University | 1597, 1712 | Sarah Cannon Cancer Center | 1626, 1680 |
| NCI Center for Cancer Research | 1517 | Organon | 1600 | Pritzker School of Medicine | 1671 | Schering AG | 1492, 1505, 1596, 1599, 1600, 1608, 1714, |
| NeoRx | 1599 | Ortho Biotech | 1537, 1538, 1599 | Pro-Pharmaceuticals | 1564, 1713 | Schering-Plough | 1531, 1601, 1608, 1727 |
| NeoOncRx | 1565 | Osaka Medical Center for Cancer & CVD (Japan) | 1682 | Progen Industries | 1538 | Scientific Protein Laboratories | 1536, 1595, 1711 |
| NeoPharm | 1564, 1588, 1703, 1704, 1713 | OSI Pharmaceuticals | 1600, 1607, 1713, 1715, 1716 | Progenics Pharmaceuticals | 1601 | Scripps Clinic | 1718 |
| Neose Technologies | 1601 | Ospedale Niguarda Ca' Granda (Italy) | 1618 | Protarga | 1707, 1713 | Scripps Institution of Oceanography | 1487, 1506, 1580 |
| Nereus Pharmaceuticals | 1491, 1506, 1580 | Ottawa Regional Cancer Centre | 1716 | Protein Design Labs (PDL) | 1532, 1535, 1537, 1539, 1600, 1601 | Scripps Research Institute | 1492, 1499, 1505, 1506 |
| New Cross Hospital (UK) | 1708 | OXiGENE | 1488, 1492, 1493 | Public Health Research Institute | 1660 | Seattle Genetics | 1565, 1586 |
| New York Hospital-Cornell Medical Center | 1511 | Paladin Labs | 1536, 1600 | Purdue University | 1721 | Sharp Healthcare | 1624 |
| New York University | 1624, 1676, 1708, 1719 | Panorama Research | 1556, 1582, 1586 | QLT | 1530, 1539, 1602 | Shenzhen Main Luck Pharmaceuticals (China) | 1531, 1542 |
| NewBiotics | 1713 | Parker Hughes Institute | 1513 | Queen Mary Hospital (China) | 1527 | Shenzhen Sancode Biotechnology (China) | 1557 |
| Nippon Organon | 1601 | Pennsylvania State University | 1595, 1713 | Rambam Medical Center (Israel) | 1674 | Shire BioChem | 1538 |
| Nippon Roche | 1535 | Perceptive BioSystems | 1596 | Repligen | 1599 | Shire Pharmaceuticals | 1714 |
| Nippon Shinyaku | 1522 | Pfizer | 1600, 1608, 1689 | Robert Wood Johnson University of Medicine and Dentistry of New Jersey | 1705 | Sidney Kimmel Comprehensive Cancer Center | 1537, 1572, 1599 |
| Norris Cotton Cancer Center | 1718 | Pfizer Global Research and Development | 1538, 1597, 1600, 1712, 1717 | Roche | 1596, 1600, 1601, 1608, 1671 | Siemens Medical Systems | 1691 |
| Northeastern University | 1557 | PG-TXL | 1597 | Roswell Park Cancer Institute | 1524, 1679 | Siemens Oncology Care Systems | 1668 |
| North Middlesex Hospital (UK) | 1616 | Pharmachemie | 1602 | Rotterdam Cancer Institute (The Netherlands) | 1555, 1708 | Sigma-Tau | 1596 |
| Northwest Biotherapeutics | 1600 | Pharmacia | 1491, 1508, 1529, 1531, 1541, 1544, 1545, 1550, 1554, 1556, 1562, 1564, 1570, 1585, 1588, 1601, 1608, 1712 | Royal Free Hospital (UK) | 1685, 1692 | SignalGene | 1492 |
| | | PharmActinium | 1600 | Royal Marsden Hospital (UK) | 1519, 1534, 1616, 1618 | Sir Charles Gardiner Hospital (Australia) | 1672 |
| | | | | Royal Prince Alfred Hospital (Australia) | 1621 | Sir Ganga Ram Hospital (India) | 1679 |
| | | | | Royal South Hants Hospital (UK) | 1675 | Southern Research Institute (SRI) | 1600, 1711, 1713, 1715 |
| | | | | Royalty Pharma | 1536 | | |
| | | | | RTP Pharma | 1602, 1714 | | |

| | | | | | | | |
|--|--|--|--|--|--|---|--|
| Southwest Foundation for Biomedical Research | 1498 | Universitäts-Krankenhaus Eppendorf (Germany) | 1552 | University of Iowa | 1490, 1536 | University of Vienna (Austria) | 1672 |
| Spectrum Pharmaceuticals | 1557, 1565, 1574, 1581, 1601, 1627 | Universite Catholique de Louvain | 1564, 1586 | University of Kentucky | 1562, 1574, 1589 | University of Virginia | 1621, 1687 |
| Sperling Sampson West | 1535 | University College Hospital (UK) | 1692 | University of Kentucky Research Foundation | 1602 | University of Washington | 1624 |
| SR Pharma | 1601 | University College London | 1601 | University of Kiel (Germany) | 1634 | University of Wisconsin | 1502, 1515, 1521, 1557, 1558, 1569, 1726 |
| SRI International | 1538, 1601 | University College Medical School (UK) | 1692 | University of Leicester (UK) | 1717 | US Oncology | 1597, 1620, 1625 |
| St. Luc University Hospital (Belgium) | 1618 | University Hospital (Belgium) | 1552 | University of Liverpool (UK) | 1646 | Utah State University | 1507 |
| St Luke's Roosevelt Hospital | 1675 | University Hospital Gasthuisberg (Leuven, Belgium) | 1618 | University of Louisville | 1554 | Vanderbilt University | 1615, 1689 |
| St. James's Hospital (UK) | 1556 | University Hospital Rotterdam (The Netherlands) | 1555 | University of Magdenburg | 1492, 1500 | Vanderbilt-Ingram Cancer Center | 1526, 1555 |
| St. Vincent's Hospital (Australia) | 1634 | University Hospitals of Cleveland | 1569 | University of Mainz (Germany) | 1552 | Variagenics | 1535, 1539 |
| Stanford University | 1500, 1579, 1620, 1669 | University of Aberdeen (Scotland) | 1527 | University of Manitoba | 1539, 1602 | Vermont Cancer Center | 1497 |
| State University of New York (SUNY) | 1553 | University of Alabama at Birmingham (UAB) | 1537, 1586, 1718 | University of Maryland | 1573, 1687 | Vertex Pharmaceuticals | 1538 |
| Stehlin Foundation for Cancer Research | 1602, 1714 | University of Arizona | 1680, 1711 | University of Miami | 1705 | Veterans Affairs Medical Center (New Orleans, LA) | 1582 |
| StressGen Biotechnologies | 1601 | University of Bochum (Germany) | 1634 | University of Michigan | 1536, 1602, 1674, 1683, 1687, 1718 | Vical | 1602 |
| Sumitomo Pharmaceuticals | 1532 | University of Bradford (UK) | 1494 | University of Minnesota | 1487, 1644 | Victoria University (New Zealand) | 1513 |
| Sungkyunkwan University School of Medicine (Korea) | 1680, 1682 | University of Brussels | 1597 | University of Mississippi Medical Center | 1553, 1554 | Vion Pharmaceuticals | 1539, 1596, 1714 |
| SUNY Downstate Medical School | 1660 | University of California | 1596, 1599, 1601, 1713 | University of Munich-Großhadern (Germany) | 1710 | Viragen International | 1599 |
| SuperGen | 1531, 1532, 1546, 1601, 1602, 1626, 1705, 1714 | University of California Davis | 1495, 1594, 1615 | University of Naples (Spain) | 1537 | Virginia Mason Medical Center | 1707, 1708 |
| Sydney Cancer Centre (Australia) | 1621 | University of California Los Angeles (UCLA) | 1496, 1505, 1522, 1685 | University of Navarre (Spain) | 1697 | Wake Forest University | 1683 |
| Syntem | 1565, 1590 | University of California San Diego (UCSD) | 1491, 1492, 1524, 1537, 1580, 1598, 1714, 1715, 1723 | University of North Carolina | 1562, 1589 | Warren Grant Magnuson Clinical Center | 1573 |
| Taiho Pharmaceutical | 1671, 1714 | University of California San Francisco (UCSF) | 1514, 1515, 1574, 1584, 1585, 1589, 1616, 1624, 1645 | University of Nottingham | 1596 | Washington School of Medicine | 1573 |
| Takeda Chemical Industries | 1491, 1507, 1712 | University of California Santa Cruz | 1487 | University of Ottawa | 1610 | Washington University | 1594, 1673 |
| TAP Pharmaceutical Products | 1602 | University of Chicago | 1621, 1671, 1687, 1719, 1727 | University of Pennsylvania | 1493, 1495, 1522, 1535, 1537, 1539, 1598 | Wayne State University | 1495, 1498, 1502, 1704, 1709 |
| Technical University of Munich (Germany) | 1575 | University of Chicago Cancer Research Center | 1509 | University of Pittsburgh | 1488, 1560, 1594, 1611, 1623, 1706, 1726, 1727 | Weill Medical College | 1718, 1724 |
| Teikoku Hormone Manufacturing | 1492, 1499 | University of Colorado | 1594, 1623 | University of Rochester | 1496, 1542 | Western Galilee Hospital (Israel) | 1674 |
| Telik | 1535, 1538, 1540, 1714 | University of Erlangen-Nuernberg (Germany) | 1672 | University of Shizuoka (Japan) | 1534 | Whitehead Institute of Biomedical Research | 1601 |
| Tetronics | 1490, 1536 | University of Florida | 1704 | University of South Florida | 1501, 1681, 1704 | William Beaumont Hospital | 1670, 1683 |
| Theradex | 1708 | University of Freiburg (Germany) | 1552, 1564 | University of South Florida Research Foundation | 1598 | Wyeth Ayerst Research | 1507 |
| Therion Biologics | 1538, 1607, 1625 | University of Glasgow (UK) | 1708 | University of Southern California (USC) | 1496, 1711, 1726 | Wyeth Pharmaceuticals | 1531, 1532, 1535, 1540, 1546, 1557, 1562, 1565, 1575, 1577, 1579, 1582, 1617 |
| Thomas Jefferson University | 1668, 1708 | University of Hawaii | 1490, 1495, 1498 | University of Texas | 1515, 1523, 1537, 1538, 1597, 1599, 1601, 1610, 1713 | Xenotech | 1508 |
| Titan Pharmaceuticals | 1602, 1616 | University of Heidelberg | 1711 | University of Texas Health Science Center | 1556, 1703, 1709 | Xenova Group | 1530, 1539, 1602 |
| Tokyo Metropolitan Komagome Hospital (Japan) | 1670 | University of Houston | 1521 | University of Texas Houston Medical School | 1677 | Xoma | 1535 |
| Tulane University | 1562, 1565, 1566, 1582 | University of Illinois | 1538 | University of Texas M. D. Anderson Cancer Center (UTMDACC) | 1554, 1558, 1571, 1574, 1583 | Yale University | 1539, 1596, 1714, 1723 |
| Tularik | 1492, 1524, 1526 | | | University of Ulm (Germany) | 1636 | Yamanouchi Pharmaceutical | 1540 |
| UCLC Saint-Luc (Belgium) | 1619 | | | University of Utah | 1487, 1565, 1583 | Yamasa | 1714 |
| UCSF Cancer Research Institute | 1645 | | | University of Veterinary Sciences (Austria) | 1711, 1721 | YM Biosciences | 1539, 1602 |
| United Therapeutics | 1595 | | | | | Zentaris | 1565, 1566, 1582, 1708, 1714 |
| Universidad de Oviedo (Spain) | 1574 | | | | | Zenyaku Kogyo | 1535 |
| | | | | | | Zivena | 1566, 1589 |

ORDERING & INQUIRY INFORMATION**FUTURE ONCOLOGY:**

FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues (several double issues) per subscription period with a free annual index listing companies/institutions and subjects covered, and a binder. FUTURE ONCOLOGY is available in hard copy format or as a PDF file sent as an attachment.

- YES, I want to order a subscription to FUTURE ONCOLOGY.

Subscription Information:

- One-year subscription is \$840 PDF, \$1,040 Hard Copy domestic and \$1,100 Hard Copy foreign. Please specify period (from _____ to _____). Additional subscriptions for the same location are \$390 each.

Back Issues:

- Volumes V4, V5, V6 Hard Copy or PDF are \$1,800.
 Volumes V4, V5, V6 and V7 Hard Copy or PDF are \$2,450.
 Volumes V6 and V7 PDF only are \$1,500.
 Specify Hard Copy _____ or PDF _____

Inquiry Information:

- Please send me a sample issue of FUTURE ONCOLOGY
 Please send me the index of Volumes 1, 2, 3, 4, 5, 6 and 7

Oncology KnowledgeBASE (nm|OK):

- YES, I want to order a order nm|OK.

nm|OK is available by subscription only and access is provided via a password. The annual subscription rate is \$3,490 for the first 'seat' and \$340.00 for each additional seat in the same physical location. Subscription rates for company-wide distribution are negotiable, based on physical location/IP designation and number of users. Please enter my subscription to nm|OK to start on

(date) _____ at \$3,490.00 _____

Additional seats # _____ at \$340.00 each _____

Total _____

Inquiry Information:

- Please call me for a walk-through the database and a complimentary pass.

All orders must be repaid or accompanied by a signed order form or P.O. #. Subscriptions to FUTURE ONCOLOGY and nm|OK will begin upon receipt of payment. Products are nonreturnable; please, feel free to call for information.

My check for \$ _____ is enclosed (make checks payable to NEW MEDICINE, INC.). Payment must accompany your order; checks must be drawn on a U.S. bank

Wire Transfer:

Washington Mutual, 400 East Main Street.
 Stockton, CA 95290. 800-374-4646. Routing #321180748.
 NEW MEDICINE INC. Account #087900008012618

Credit Card: Visa AmEx M/C Exp. Date: _____

| | | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

Bill me on P.O. #: _____

Signature: _____

Name: _____

Title: _____ Company: _____

Address: _____

City: _____ State: _____

Zip Code: _____ Country: _____

Telephone: _____ Fax: _____

E-mail _____

Return to: NEW MEDICINE, INC.:

P.O. Box 909 • Lake Forest • CA 92630
 Telephone: (949) 830-0448 • Fax: (949) 830-0887
 E-mail: info@newmedinc.com
 Web Sites: www.newmedinc.com
 www.oncologyknowledgebase.com
 www.nmok.net

FUTURE ONCOLOGY Staff:

| | |
|-----------------------------|-----------------|
| PUBLISHER AND EDITOR: | Katie Siafaca |
| VICE PRESIDENT-OPERATIONS: | Beth Schweitzer |
| EDITOR: | Jason Dugan |
| ASSOCIATE EDITOR: | Tanya MacLean |
| ASSOCIATE EDITOR: | Jill Protzman |
| ASSISTANT EDITOR: | Jessica Goshi |
| DIRECTOR-MARKETING & SALES: | Katrina Ruegg |
| DESIGN & PRODUCTION: | Jill Burch |

Sale of NEW MEDICINE hard copy and electronic publications is made under the following conditions:

Unauthorized photocopying, distribution or electronic storage is strictly prohibited. Information incorporated in NEW MEDICINE products is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held liable for errors. Errors, when discovered, will be corrected. Subscriptions may not be canceled, but may be transferred.